Latest Insider Transactions at Tarsus Pharmaceuticals, Inc. (TARS)
This section provides a real-time view of insider transactions for Tarsus Pharmaceuticals, Inc. (TARS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Tarsus Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Tarsus Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Scott W Morrison Director |
SELL
Bona fide gift
|
Direct |
6,016
-100.0%
|
-
|
|
Sep 15
2024
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+18.14%
|
-
|
|
Aug 12
2024
|
William J Phd Link |
SELL
Open market or private sale
|
Indirect |
35,000
-92.83%
|
$910,000
$26.27 P/Share
|
|
Aug 12
2024
|
William J Phd Link |
BUY
Other acquisition or disposition
|
Direct |
27,116
+13.96%
|
-
|
|
Aug 12
2024
|
William J Phd Link |
BUY
Other acquisition or disposition
|
Indirect |
10,446
+50.0%
|
-
|
|
Aug 12
2024
|
William J Phd Link |
SELL
Other acquisition or disposition
|
Indirect |
74,892
-68.15%
|
-
|
|
Jun 24
2024
|
William J Phd Link |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+2.34%
|
-
|
|
Jun 24
2024
|
Andrew D. Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+34.54%
|
-
|
|
Jun 24
2024
|
Rosemary A Crane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+38.51%
|
-
|
|
Jun 24
2024
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+24.45%
|
-
|
|
Jun 24
2024
|
Bhaskar Chaudhuri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+38.51%
|
-
|
|
Jun 24
2024
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+41.7%
|
-
|
|
Jun 24
2024
|
Elizabeth Yeu Lin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+38.51%
|
-
|
|
Jun 18
2024
|
Jeffrey S Farrow Officer |
SELL
Open market or private sale
|
Direct |
10,445
-36.55%
|
$282,015
$27.47 P/Share
|
|
Jun 17
2024
|
Jeffrey S Farrow Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,881
+49.38%
|
-
|
|
Mar 18
2024
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Direct |
10,415
-28.25%
|
$312,450
$30.6 P/Share
|
|
Mar 18
2024
|
Bryan Wahl General Counsel |
SELL
Open market or private sale
|
Direct |
4,436
-9.77%
|
$133,080
$30.6 P/Share
|
|
Mar 18
2024
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,766
-8.1%
|
$142,980
$30.6 P/Share
|
|
Mar 18
2024
|
Seshadri Neervannan Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,879
-7.01%
|
$146,370
$30.6 P/Share
|
|
Mar 18
2024
|
Dianne C. Whitfield Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
4,314
-11.21%
|
$129,420
$30.6 P/Share
|
|
Mar 15
2024
|
Bobak R. Azamian President/CEO and Board Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
28,274
+43.4%
|
-
|
|
Mar 15
2024
|
Bryan Wahl General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
12,038
+20.96%
|
-
|
|
Mar 15
2024
|
Aziz Mottiwala Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,938
+18.02%
|
-
|
|
Mar 15
2024
|
Seshadri Neervannan Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,245
+15.98%
|
-
|
|
Mar 15
2024
|
Dianne C. Whitfield Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,711
+23.33%
|
-
|
|
Dec 27
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
8,000
-0.95%
|
$160,000
$20.22 P/Share
|
|
Dec 20
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
40,000
-2.3%
|
$800,000
$20.16 P/Share
|
|
Dec 20
2023
|
Jose M. Trevejo CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,252
-50.01%
|
$45,040
$20.0 P/Share
|
|
Dec 15
2023
|
Andrew D. Goldberg Director |
BUY
Open market or private purchase
|
Direct |
1,000
+25.0%
|
$18,000
$18.96 P/Share
|
|
Dec 02
2023
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+41.67%
|
-
|
|
Nov 30
2023
|
Bryan Wahl General Counsel |
SELL
Open market or private sale
|
Direct |
8,356
-20.72%
|
$133,696
$16.31 P/Share
|
|
Nov 30
2023
|
Dianne C. Whitfield Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
8,355
-23.78%
|
$133,680
$16.31 P/Share
|
|
Nov 29
2023
|
Bryan Wahl General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
23,920
+37.23%
|
-
|
|
Nov 29
2023
|
Dianne C. Whitfield Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,920
+40.5%
|
-
|
|
Nov 15
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
8,000
-0.3%
|
$144,000
$18.61 P/Share
|
|
Oct 18
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
8,000
-0.89%
|
$104,000
$13.24 P/Share
|
|
Oct 05
2023
|
Jose M. Trevejo CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,604
-26.26%
|
$28,872
$18.0 P/Share
|
|
Sep 20
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
8,000
-0.89%
|
$136,000
$17.21 P/Share
|
|
Sep 15
2023
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+50.0%
|
-
|
|
Aug 23
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
8,000
-0.88%
|
$136,000
$17.23 P/Share
|
|
Aug 15
2023
|
Elizabeth Yeu Lin Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
9,506
+37.47%
|
$152,096
$16.8 P/Share
|
|
Jul 19
2023
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,400
-4.98%
|
$48,000
$20.05 P/Share
|
|
Jul 19
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
103,900
-5.14%
|
$1,974,100
$19.66 P/Share
|
|
Jul 12
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
9,000
-0.88%
|
$153,000
$17.35 P/Share
|
|
Jun 21
2023
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Indirect |
8,000
-0.78%
|
$144,000
$18.63 P/Share
|
|
Jun 16
2023
|
Bhaskar Chaudhuri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
Jun 16
2023
|
Rosemary A Crane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
Jun 16
2023
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
Jun 16
2023
|
Elizabeth Yeu Lin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
Jun 16
2023
|
Andrew D. Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|